News | Hypertension | December 14, 2018

Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension

Research endeavor marks a clinical research expansion of the CorVista platform

Analytics 4 Life and Actelion to Develop New Diagnostics for Pulmonary Hypertension

December 14, 2018 — Digital health company Analytics 4 Life and Actelion Pharmaceuticals Ltd. announced a collaborative agreement to investigate the use of Analytics 4 Life’s diagnostic imaging technology in pulmonary hypertension. The first 500-person clinical study has been initiated for this serious, life-threatening condition affecting millions of people worldwide.

Analytics 4 Life seeks to use machine learning technologies to develop a more complete picture of cardiac health with a single, non-invasive test. Actelion, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, specializes in the science and treatment of pulmonary arterial hypertension (PAH), a type of pulmonary hypertension – a cardiovascular disorder with an average life expectancy of only seven to nine years once diagnosed and therapy is initiated. On average, there is a three-year delay from a patient presenting with symptoms to receiving an accurate diagnosis of PAH from right heart catheterization. The goal of this collaboration is to diagnose more patients with all types of pulmonary hypertension earlier, leading to improved outcomes.

The agreement will focus on Analytics 4 Life’s CorVista platform. CorVista is a non-invasive medical imaging system designed to acquire and process patient data and display results in a report accessible via a secure web portal. The system scans signals emitted by the body without radiation, exercise or pharmacologic stress, and wirelessly transmits the signal package to the cloud for processing and report generation. Physicians can interpret and use the results as part of an assessment of their patient.

CorVista operates on a secure, cloud-based platform amenable to clinical investigation for a myriad of cardiovascular diseases. Paired physiologic signals and clinical results from gold-standard tests are collected and wirelessly transmitted to the cloud, where machine learning analysis can be performed to develop clinically relevant algorithms that can ultimately be embedded into the CorVista system. It has already been tested in over 2,600 patients in the Coronary Artery Disease Learning and Algorithm Development (CADLAD) clinical study.

For more information: www.analytics4life.com


Related Content

News | Hypertension

May 19, 2025 — Gradient Denervation Technologies recently announced the company’s pulmonary denervation system has ...

Home May 20, 2025
Home
News | Hypertension

April 9, 2025 — Idorsia Ltd recently announced that the US Food & Drug Administration (FDA), after having released ...

Home April 09, 2025
Home
News | Hypertension

Mar. 10, 2025-- Corcept Therapeutics Inc., a commercial-stage company engaged in the discovery and development of ...

Home March 11, 2025
Home
News | Hypertension

Jan. 9, 2025 — Gender-based racism through microaggressions may be linked to higher blood pressure postpartum and beyond ...

Home January 14, 2025
Home
News | Hypertension

Jan. 8, 2025 — Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines ...

Home January 08, 2025
Home
News | Hypertension

Dec. 11, 2024 — Older adults whose blood pressure fluctuates over time may be more likely to have problems with thinking ...

Home December 19, 2024
Home
News | Hypertension

June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative ...

Home June 28, 2024
Home
News | Hypertension

June 6, 2024 — A substantial portion of young athletes are at risk of hypertension, according to a study presented at ...

Home June 06, 2024
Home
News | Hypertension

May 16, 2024 — People were more likely to develop a type of treatment-resistant hypertension when they experienced ...

Home May 16, 2024
Home
News | Hypertension

May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. Bioelectronic medicine ...

Home May 08, 2024
Home
Subscribe Now